Avutometinib + Defactinib for Ovarian and Cervical Cancer

(DURAFAK Trial)

Recruiting in Palo Alto (17 mi)

+2 other locations

Overseen by Christina Washington, MD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: University of Oklahoma

Must not be taking: Warfarin, Strong CYP inhibitors, P-gp inhibitors

Disqualifiers: Low grade serous ovarian cancer, Brain metastases, Hepatitis, HIV, others

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.

Will I have to stop taking my current medications?

The trial does not specify if you must stop all current medications, but you cannot take certain drugs like warfarin, strong CYP2C9 and CYP3A4 inhibitors or inducers, and P-glycoprotein inhibitors or inducers. It's best to discuss your current medications with the trial team to see if any adjustments are needed.

What makes the drug combination Avutometinib + Defactinib unique for treating ovarian and cervical cancer?

The combination of Avutometinib and Defactinib is unique because it targets the MEK and FAK pathways, which are involved in cancer cell growth and survival, offering a novel approach compared to traditional chemotherapy treatments for ovarian and cervical cancer. ^{1 2 3 4 5}

Research Team

Christina Washington, MD

Principal Investigator

OU Health, Stephenson Cancer Center

Eligibility Criteria

This trial is for women over 18 with certain types of gynecological cancers that have mutated genes and have worsened after at least one treatment. They must be relatively healthy, not pregnant or breastfeeding, able to use birth control, and not have had recent surgeries or certain other treatments.

Inclusion Criteria

You have a disease that can be accurately measured using specific medical guidelines.

My gynecological cancer has specific genetic changes.

There must be enough tissue samples for confirmation before starting treatment.

Exclusion Criteria

I am currently taking warfarin.

I haven't taken any P-gp affecting drugs in the last 14 days.

Subjects with a history of hypersensitivity to any of the inactive ingredients of the investigational product

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Avutometinib (VS-6766) and Defactinib orally as per study procedures

2 years

Regular visits for physical examinations, vitals, and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Avutometinib (VS-6766) (MAPK Inhibitor)
• Defactinib (Focal Adhesion Kinase Inhibitor)

Trial Overview The study tests the combination of two drugs, Avutometinib (VS-6766) and defactinib, on patients with specific ovarian or cervical cancers. It aims to evaluate their effectiveness in controlling cancer growth and assess the safety profile of this drug regimen.

Participant Groups

Group I: Avutometinib (VS-6766) + Defactinib Experimental Treatment 1 Intervention

Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).

Who Is Running the Clinical Trial?

University of Oklahoma

Lead Sponsor

Trials

484

Recruited

95,900+

Dr. Scott Rollins

University of Oklahoma

Chief Executive Officer since 2016

PhD in Immunology from the University of Oklahoma

Dr. Ondria Gleason

University of Oklahoma

Chief Medical Officer

MD from the University of Oklahoma College of Medicine

Verastem, Inc.

Industry Sponsor

Trials

42

Recruited

2,800+

Findings from Research

Combining osimertinib with either selumetinib or cetuximab significantly improved treatment response rates in EGFR-mutated non-small cell lung cancer (NCLC) models, achieving response rates of 50% to 90% and median progression-free survival times of up to 28 weeks.

The study identified that resistance to these combination therapies is linked to Hedgehog pathway activation, suggesting that targeting this pathway alongside EGFR inhibition could enhance treatment efficacy in resistant cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. Della Corte, CM., Ciaramella, V., Cardone, C., et al.[2022]

The combination of trametinib and afuresertib was poorly tolerated at the starting dose, leading to dose-limiting toxicities, but an intermittent dosing schedule showed better tolerability, suggesting a potential for safer administration.

Among 20 patients with advanced solid tumors, the study reported one partial response and four cases of stable disease, indicating some efficacy, but the overall response rate was low, warranting further investigation into alternative dosing strategies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Tolcher, AW., Patnaik, A., Papadopoulos, KP., et al.[2015]

The Phase III NeoADAURA study is designed to evaluate the effectiveness of neoadjuvant osimertinib, an advanced EGFR inhibitor, in combination with chemotherapy compared to chemotherapy alone in patients with resectable stage II-IIIB N2 EGFR mutation-positive non-small-cell lung cancer (NSCLC).

The primary goal of the study is to assess the major pathological response at the time of surgery, while also examining secondary outcomes such as event-free survival and overall survival, ensuring a comprehensive evaluation of osimertinib's safety and efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Tsuboi, M., Weder, W., Escriu, C., et al.[2022]

References

1. United States pubmed.ncbi.nlm.nih.gov

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. [2020]

3. Germany pubmed.ncbi.nlm.nih.gov

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. [2015]

4. England pubmed.ncbi.nlm.nih.gov

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. [2022]

5. China pubmed.ncbi.nlm.nih.gov

Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. [2020]